Analysis on whether pazopanib (Victor) must be taken for a long time once it is taken

Pazopanib is an oral multi-target tyrosine kinase inhibitor mainly used to treat advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). It blocks tumor angiogenesis and cell proliferation by inhibiting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and other tyrosine kinase pathways, thus delaying tumor development. Because the mechanism of action is related to the continued growth of tumors, many patients and their families are concerned about whether they must take long-term medication once they are started.

The use of pazopanib should be based on an individualized treatment plan, usually as prescribed by a doctor at a fixed daily oral dose. Clinically, the course of drug treatment is not fixed, and it is usually recommended to continue taking the drug as long as the patient can tolerate it and the disease is under control. If serious adverse reactions occur or the condition changes, the doctor may suspend the medication, adjust the dose, or decide to discontinue the medication based on efficacy evaluation. Therefore, pazopanib does not have to be used for a lifetime once it is taken, but should be dynamically adjusted according to the patient's condition.

While taking pazopanib, regular imaging evaluation and laboratory tests are key to judging efficacy and safety. By monitoring progression-free survival (PFS), tumor shrinkage, and adverse reactions, doctors can decide whether to continue taking the drug, adjust the dose, or temporarily discontinue the drug. For example, for patients whose tumors have significantly shrunk and whose side effects are controllable, maintenance treatment can be continued; if their condition is stable or if intolerable side effects occur, intermittent medication or drug discontinuation strategies may be adopted.

Although long-term use of pazopanib can maintain the anti-tumor efficacy, it may also increase the risk of side effects, such as abnormal liver function, hypertension, and hand-foot syndrome. Therefore, doctors will develop individualized medication strategies based on patient tolerance, disease progression, and quality of life. Patients should follow medical advice during medication, report discomfort symptoms in a timely manner, and undergo regular review to balance efficacy and safety and achieve the best therapeutic effect.

Reference link:https://www.drugs.com